clinical trial · NCT07004439
A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice
Implantica CE Reflux Ltd.·N/A·not yet recruiting·n = 500
Gastroesophageal Reflux DiseaseRefluxStop™ implantation
brief summary
A post-market retrospective and prospective, open label, multicenter, single-arm registry study using standard clinical procedures to record available and/or new data to evaluate the safety and performance of RefluxStop™ for the treatment of subjects suffering from GERD. Following surgery, patients will have follow-ups visits at 3 and 6 months and annually up to 7 years.
started
Sep 15, 2025
primary completion
Aug 1, 2029
completion
Aug 1, 2035
last updated
Jun 4, 2025
official title
A Post-market Registry Study Based on Standard Clinical Care to Assess Safety and Performance of RefluxStop™ in the Treatment of Gastroesophageal Reflux Disease (GERD) in General Hospital Practice
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol